# University of Arizona Cancer Prevention Clinical Trials Network (UA CP-CTNet)

> **NIH NIH UG1** · UNIVERSITY OF ARIZONA · 2021 · $1,918,750

## Abstract

PROJECT SUMMARY
Advances in molecular understanding of the process of carcinogenesis have led to the study of an increasing
number of agents to intercept the early phases of cancer development, including the recent interest in
immunoprevention. The overall objective of University of Arizona Cancer Prevention Clinical Trials Network (UA
CP-CTNet) is to perform early phase clinical trials to evaluate the biologic effects of putative preventive agents
and to determine clinically relevant correlates in order to identify agents with good safety profiles and preliminary
efficacy for definitive Phase III trials.
The UA CP-CTNet consists of a team of physicians from diverse specialties, statisticians, clinical staff, data
managers, pathologists, translational scientists, and other personnel with extensive experience in early phase
clinical trials of cancer preventive agents and in translational research in various organ sites.
Specifically, the UA CP-CTNet will:
 • Efficiently design and conduct Phase 0/I/II clinical trials to assess the cancer preventive potential of
 repurposed drugs that affect multiple chronic diseases, well-characterized nutraceutical agents,
 regional/topical drug delivery, and immune modulators, identified from translational research,
 epidemiological studies, and/or clinical research.
 • Characterize the clinical activity and biological effects of putative cancer preventive agents on their
 defined molecular/biochemical targets, the immune surveillance network, surrogate endpoints associated
 with carcinogenesis, and other biological effect markers identified in preclinical studies.
 • Develop further scientific insights into the mechanisms of cancer prevention by the agents studied and
 to develop novel potential markers as determinants of response and for selecting subpopulations who
 may differentially benefit from the studied agent.
Through the proposed research, we expect to conduct rigorously designed early phase cancer prevention clinical
trials that determine the clinical activity and biological effects of potential preventive agents. The research
findings will further scientific insights into the mechanisms of cancer prevention and develop novel potential
biomarkers as determinants of response. Scientific and clinical evidence generated from these early phase
cancer prevention clinical trials will contribute significantly to “go-no go” decisions for further clinical development
of putative agents for cancer prevention.

## Key facts

- **NIH application ID:** 10240570
- **Project number:** 5UG1CA242596-03
- **Recipient organization:** UNIVERSITY OF ARIZONA
- **Principal Investigator:** Julie E Bauman
- **Activity code:** UG1 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $1,918,750
- **Award type:** 5
- **Project period:** 2019-08-16 → 2024-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10240570

## Citation

> US National Institutes of Health, RePORTER application 10240570, University of Arizona Cancer Prevention Clinical Trials Network (UA CP-CTNet) (5UG1CA242596-03). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10240570. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*